Cardiovascular Risk Associated With Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention

1,397 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond. (2008, background): “Further studies, conclusively demonstrated that selective COX-2 inhibitors may tip the natural balance between prothrombotic thromboxane A2 (TxA2) and antithrombotic prostacyclin (PGI2) potentially increasing the possibility of a thrombotic cardiovascular event (17-19).”
Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. (2007, background): “Celecoxib/ placebo administration for all patients remaining on study was permanently discontinued on January 19, 2005, after an announcement concerning the potential association of celecoxib with increased risk of major cardiovascular events in a long-term, colorectal adenoma prevention study (the ”
Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer (2017, background): “Moreover, celecoxib does not present adverse gastrointestinal effects [237] and does not produce cardiovascular problems [238].”